PCOS Fertility Tests to Ask For, and What Each One Actually Changes

What Fertility Tests Should You Actually Ask For With PCOS?

A test is only worth ordering if an abnormal result would change what happens next — and several tests marketed to people with PCOS fail that bar. This page is part of the site’s full PCOS fertility coverage, and it runs through the tests worth raising with a clinician, what each one measures, when in the cycle it needs to be drawn if timing matters, and specifically what a result would actually alter. Everything below is a question to bring to an appointment, not a self-directed panel to order and interpret alone — a result only means something in the context a clinician can put it in.

You may see PCOS written as polyendocrine metabolic ovarian syndrome (PMOS), after a 2026 global consensus of more than 50 organisations renamed it. Every test below applies under either name — only the label changed.

Why the Semen Analysis Belongs at the Top of This List

A semen analysis is the single most skipped test on a PCOS fertility work-up, and it should not be. Male factors contribute wholly or in part to 45.1% of infertility cases overall, per the population data behind the 2026 WHO infertility guideline — a figure in line with older estimates that put male-factor-alone and combined male-and-female-factor infertility together at roughly a third to half of all cases. PCOS does not lower that share. A 2025 case-control study found that 22.5% of male partners of women with anovulatory PCOS had a pathological semen result, close to double the 13.2% rate in a comparison group (Aschauer et al. 2025) — and a female PCOS diagnosis was not associated with the male partner’s result in either direction.

What it measures: semen volume, sperm concentration, total sperm number, motility, vitality, and morphology, compared against reference values built from a study of more than 4,500 men across 14 countries.

Timing: no cycle-day requirement — it does not depend on the female partner’s cycle at all, which is part of why it is easy to schedule and easy to keep putting off.

What it changes: a pathological result redirects part of the treatment conversation toward the male partner — lifestyle factors, a urology referral, or a different assisted-reproduction pathway — rather than assuming every additional cycle of female-side treatment is the right next step. It is cheap, non-invasive, and returns results in days, which makes deferring it a poor trade against what it can rule in or out.

Thyroid and Prolactin: Ruling Out the Conditions That Look Like PCOS

What they measure: TSH (thyroid-stimulating hormone) and prolactin, two hormones that, when abnormal, cause irregular cycles and anovulation that can look identical to PCOS on the surface.

Timing: no strict cycle-day requirement, though prolactin is best drawn without recent breast stimulation or a stressful venipuncture experience, both of which can transiently raise it.

What it changes: an abnormal TSH or prolactin result changes the diagnosis, not just the fertility plan. The 2023 international PCOS guideline requires thyroid disease and hyperprolactinemia to be ruled out before a PCOS diagnosis is confirmed at all, because both conditions have their own specific treatments that restore ovulation directly — treating anovulation as PCOS-related when it is actually a thyroid or prolactin problem means treating the wrong mechanism entirely.

Day-3 (or Day 2–5) Hormone Panel: LH, FSH, Testosterone, SHBG

What it measures: baseline pituitary and ovarian hormone levels — LH, FSH, total and free testosterone, and sex hormone-binding globulin (SHBG).

Timing: this is the one panel on this page where timing genuinely matters. It is drawn on cycle day 2 through 5 — early in a cycle, before hormone levels shift with follicle development — which means an irregular or absent cycle makes timing this panel correctly a real practical problem worth raising directly with whoever orders it.

What it changes: these values feed the diagnostic picture and treatment planning rather than answering one question on their own. An elevated LH-to-FSH ratio or free testosterone supports a PCOS diagnosis; a low SHBG flags a higher free-androgen burden relevant to some treatment decisions. None of these values in isolation confirms or rules out fertility potential, which is why they are interpreted as a set rather than one number at a time.

AMH: What It Actually Predicts, and What It Does Not

What it measures: anti-Müllerian hormone, a marker of the remaining pool of small ovarian follicles — often elevated in PCOS because of the follicle-arrest pattern the condition produces.

Timing: unlike the day-3 panel, AMH does not require a specific cycle day; it stays relatively stable across a cycle, which is one reason it gets ordered casually.

What it changes — and what it does not: AMH predicts how many eggs an ovary is likely to yield during IVF stimulation, and predicts it well. It does not predict whether or how quickly you will conceive naturally. A prospective cohort study of 750 women aged 30 to 44 trying to conceive found that women with a low AMH (below 0.7 ng/mL) had essentially the same probability of conceiving within 6 and 12 cycles as women with normal AMH — 65% versus 62% at 6 cycles, not a statistically meaningful gap — and the study’s own conclusion was direct: these biomarkers should not be used to assess natural fertility. A separate individual-patient-data meta-analysis found the same split in what AMH and antral follicle count actually forecast: strong prediction of ovarian stimulation response, weak-to-no prediction of an ongoing pregnancy.

Tubal Assessment: Confirming the Pipes Are Open

What it measures: whether the fallopian tubes are patent (open), most often checked by hysterosalpingogram (HSG) — an X-ray using contrast dye — or a saline-based ultrasound alternative.

Timing: performed in the first half of the cycle, after bleeding has stopped and before ovulation, to avoid disrupting a possible pregnancy.

What it changes: a blocked tube redirects the entire treatment conversation toward IVF, which bypasses the tubes entirely, rather than ovulation-induction medication, which depends on the tubes working. The American Society for Reproductive Medicine’s standard female fertility work-up includes tubal assessment as routine regardless of a PCOS diagnosis, precisely because a known ovulation problem does not rule out an independent tubal one. Anyone taking metformin should mention it before an HSG specifically, since the procedure uses iodinated contrast. What the HSG appointment actually involves, timing and honest pain expectations included, is covered in full here.

Glucose and Insulin Status: OGTT or Fasting Levels

What it measures: a 75g oral glucose tolerance test (OGTT), or fasting glucose and insulin, assessing insulin resistance and pre-diabetes risk.

Timing: fasting, and not cycle-dependent.

What it changes: the 2023 international PCOS guideline recommends this testing as part of routine PCOS metabolic screening, and results here shape both the pregnancy-risk conversation — gestational diabetes risk is higher with pre-existing insulin resistance — and which weight-management or insulin-sensitising approach a clinician might discuss as part of a broader fertility plan. It is not, on its own, a fertility test in the sense of predicting whether or when you will conceive.

Two Tests Not Worth Paying For

Not every test marketed to people trying to conceive with PCOS changes anything a clinician would do differently, and two show up on this list specifically because they are common, expensive, and unsupported.

Direct-to-consumer saliva or dried-urine hormone panels. These test the same broad hormone categories as standard bloodwork through a different, non-serum sample type, marketed on the idea that they capture a fuller hormonal picture. No PCOS or fertility guideline recommends them, and even research published by the industry’s own manufacturers concludes that serum remains the most accurate, validated method for hormone measurement. The full DUTCH test evidence review covers one widely sold version of this panel — nothing in it changes a fertility work-up.

Unvalidated food-sensitivity testing. IgG-based food-sensitivity panels are marketed on the premise that a positive result identifies foods driving inflammation, hormone imbalance, or fertility problems. The specialist body that reviewed this evidence concluded the opposite: an EAACI task force found that IgG antibodies to food represent a normal immune response to repeated exposure — a sign of tolerance, not intolerance — and explicitly recommended against using IgG testing to diagnose food-related symptoms of any kind. A positive result on one of these panels does not identify a food to eliminate, and no fertility guideline uses this test for any purpose.

Who Should Ask for All of This at Once, Not One Test at a Time

Testing both partners and all of the above categories together, rather than waiting for each result before ordering the next, matters more the longer a couple has already been trying. The referral timelines for when to see a fertility specialist are covered on that page, along with what a specialist adds beyond a first GP visit. This page describes what to ask for and why each test matters; it does not replace the clinician who orders, times, and interprets the actual results, and nothing here is a substitute for that conversation.